FLT3 and acute myeloid leukemia: Previously published data had shown moderate inhibitory activity of Setanaxib on the proliferation of FLT3-ITD-positive AML cell lines, including MV4-11 cells, MOLM13 cells, and stable FLT3-ITD-transduced murine 32D cells [25].